Lates News

Novo Nordisk announced multiple research results at the 2025 annual meeting of the European Association for the Study of Diabetes (EASD). Among them, the STEP UP trial showed that participants receiving higher doses of semaglutide (7.2 mg weight loss version) achieved an average weight loss of 21% compared to the placebo group, with one-third of participants experiencing a weight loss of 25% or more. In the STEP UP trial, 84.5% of the weight loss achieved with semaglutide 7.2 mg was attributed to fat reduction. Subgroup analysis results from the STEP UP trial showed no significant differences in lean body weight and muscle mass changes in participants receiving semaglutide 7.2 mg compared to the placebo group, and muscle function was also preserved.